PCI for Long Coronary Lesion
|
|
- Emory Dominic Harrison
- 5 years ago
- Views:
Transcription
1 PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES
2 In the Bare Metal Stent Era
3 Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis Minimum in-stent area 6 35 Stent Length De Feyter. Circulation 1999; 1:
4 Spot Stenting vs. Long Stent 6 Months MACE Restenosis Rate Spot stenting Long stenting P<.5 P<.5 38 % 39 % 22 % 25 % Colombo A et al, J Am Coll Cardiol 21;38:
5 Single Stent vs. Multiple Stent Restenosis Rate % P = NS One stent (n=62) Two stents (n=62) Hoffmann R, et al. Am J Cardiol 22:9:46-464
6 Single Stent vs. Multiple Stent Contrast agent Cost-Effectiveness Intervention Cost ml Euros P =.56 P < One stent Two stent Hoffmann R, et al. Am J Cardiol 22:9:46-464
7 Stenting with Bare Metal Stent for Long Coronary Lesion It was suggested that Spot stenting Single stent
8 What is changing? In the Era of Drug Eluting Stent
9 No Increase of Restenosis with Increasing SES length SIRIUS : Sirolimus Eluting Stent % Control Sirolimus Stent Length (mm) TCT, Oct 22
10 TLR vs. Stent Length SIRIUS : Sirolimus Eluting Stent % Control Sirolimus Stent Length (mm) TCT, Sep 23
11 Relative Reduction of Restenosis Non-diabetic Ref Dia SIRIUS : Sirolimus Eluting Stent > 3.mm mm < 2.5mm < 12mm 81.7 % 79.8 % 77.6 % Lesion length mm 81.2 % 79.2 % 76.6 % 15mm 8.4 % 77.9 % 74.8 % Diabetic Ref Dia > 3.mm mm < 2.5mm < 12mm 78. % 74.1 % 69.6 % mm 77. % 72.7 % 67.8 % 15mm 75.3 % 7.2 % 64.5 % TCT, Oct 22
12 Restenosis in Lesions 1mm in stented segment TAXUS II : Paclitaxel Eluting Stent % P < Combined control (n=144).8 Combined TAXUS (n=133) Grube E, ACC, 23
13 Impact of Lesion Length in TAXUS IV Restenosis (analysis segment) 5 Control (n=652) TAXUS (n=662) P=.4 Restenosis P= P< N=9 N=9 N=124 N=153 N=53 N=47 <1 mm 1-2 mm >2 mm Lesion length (mm)
14 Full Metal Jacket in DES 71 patients (153 lesion, 29 SES) Lesion length : 52.1±23.1mm Reference vessel diameter: 2.59±.58mm Stented segment : 83.6±23.9mm Glycoprotein IIb/IIIa inhibitors: 65% Orlic D, ACC, 24
15 Full Metal Jacket in DES In-hospital events (postprocedure) Q-MI Non Q-MI (CK-MB>3 normal) 3 days outcomes Subacute stent thrombosis Death due to MI 6-month follow-up TLR Sirolimus (n=71) 1(1.4%) 15(21.1%) 1(1.4%) 1(1.4%) 7.2% Orlic D, ACC, 24
16 RESEARCH registry Stented length > 36 mm (de novo lesion) Study population Stented length Stents per lesion 6-month angiography 96 pts( 12 lesions) 62 ± 21mm( mm) 2.7 ±.9 (2-6) 67 patients (71%) Binary restenosis (DS > 5% ) : 11.9% Serruys PW ACC, 24
17 6-month Angiographic Follow-Up RESEARCH registry Proximal In-stent Reference vsl diameter Minimal lumen diameter % diameter stenosis Late lumen loss.2.13 In-lesion binary restenosis : 11.9% Distal Serruys PW ACC, 24
18 Clinical Follow-Up at 32 Days RESEARCH registry % 1 7% 5 5% 2% % Death MI TLR MACE Serruys PW ACC, 24
19 Comparison of Late Loss Stented length (mm) Late loss (mm) Kobayashi Tulip -angio guided Tulip -IVUS guided IMP ULSE-1 stent IM PULSE-2 stent ADVANCE RESEARCH Serruys PW ACC, 24
20 Long Cypher Multicenter Prospective non- Randomized Registry study for DES in Very Long Lesion ; -Preliminary Data- Coordinating center : Asan Medical Center, Collaborating centers Ajou University Medical Center, Catholic University of Korea, St Mary s Hospital, Chonnam Nat l University Hospital, Keimyung University Dongsan Medical Center, Korea University Kuro Hospital, Samsung Medical Center, Seoul National University Hospital, Yonsei University Severance Hospital, Yonsei University Wonju Christian Hospital, SJ Park SJ Tahk KB Seung MH Jeong KS Kim DJ Oh HC Gwon Lee MM, Koo BK YS Jang JH Yoon
21 Long Cypher Prospective, Non-randomized Multicenter, Registry Study in Korea From March 23 - February 24 De-novo Lesions ( 24mm) 487 patients, 597 lesions Cypher stent ( 28mm) 338 patients, 424 lesions Mean stent length : 41mm (28-92 mm) BMS stent ( 28mm) 149 patients, 173 lesions Mean stent length : 37mm (28 73 mm)
22 Long Cypher Lesion Characteristics Cypher Control P value (n=424) (n=173) Lesion length (mm) 33. ± ± Proximal reference (mm) 3.2 ± ±.55 <.1 Distal reference (mm) 2.63 ± ±.59 <.1 MLD (mm).72 ± ± Diameter stenosis (%) 74.2 ± ±
23 Stenting Procedure Long Cypher Cypher Control P value (n=424) (n=173) Used No of stents 1.55 ± ±.54 <.1 Overlapping 196 (46%) 44 (25%) <.1 Contiguous stent length (mm) 4.8 ± ± Maximal inflation pressure (atm) 15.4 ± ± 3.3 <.1 Maximal balloon size 3.31 ± ±.51.8 Balloon-to-artery ratio 1.11 ± ±.14 <.1 IVUS guidance 33 (72%) 71 (41%) <.1 Use of Abciximab 11 (3%) 7 (4%).492
24 Long Cypher Post-Procedure QCA Analysis Cypher Control P value (n=424) (n=173) Proximal reference (mm) 3.9 ± ±.55 <.1 Distal reference (mm) 2.56 ± ±.52 <.1 MLD (mm) 2.72 ± ±.54 <.1 Diameter stenosis (%) 2.7 ± ± Acute gain 2. ± ±.68.22
25 Angiographically normal reference vessels actually had 28-38% plaque burden when seen by IVUS N Proximal reference (mm 2 ) EEM CSA (mm 2 ) Lumen CSA (mm 2 ) Plaque burden (%) Distal reference EEM CSA (mm 2 ) Lumen CSA (mm 2 ) Plaque burden (%) ± ± ± ± ± ± 1.6
26 Postprocedural Stent CSA N 67 Stent (mm 2 ) EEM CSA Stent CSA 9.4 ± ± 2.5
27 In-Hospital Outcomes Long Cypher Procedural success * Death MI Q wave Non-Q wave *** Stent thrmbosis TLR TVR Cypher (n=338) 97.8% 29 (9%) 29 (9%) Control (n=149) 94.8% 1 (.7%) ** 18 (12%) 18 (12%) * Final TIMI flow 2 and residual diameter stenosis 3% ** No reflow after multivessel PCI *** CK-MB 3 times normal value P value
28 3-Day Outcomes Long Cypher Death Non-cardiac Cardiac MI Q wave Non-Q wave Sent thrombosis TLR TVR Cypher (n=338) 1 (.3%) * 1 (.3%) * Due to intracranial hemorrhage, 5 days after intervention Control (n=149) 1 (.7%) 1 (.7%) P value
29 6-Month Outcomes Long Cypher Death Non-cardiac Cardiac MI Q wave Non-Q wave Stent thrombosis TLR Repeat PCI CABG MACE Cypher (n=162) 1 (.6%) 1 (.6%) 1 (.6%) 1 2 (1.1%) Control (n=127) 1 (.8%) 1 (.8%) 18 (14.2%) (15.%) P value <.1 <.1
30 Long Cypher 6-Month QCA Analysis Cypher Control P value (n=117) (n=97) Proximal reference(mm) 3. ± ± Distal reference (mm) 2.6 ± ± MLD (mm) 2.54 ± ±.76 <.1 Diameter stenosis (%) 9.3 ± ± 22.2 <.1 Late loss (mm).31 ± ±.72 <.1 Restenosis 3 (2.6%) 42 (43.3%) <.1
31 Late Loss Long Cypher mm 2. SES (n=11) BMS (n=79) P<.1 P< P= P= In-segment Proximal edge In-stent Distal edge
32 Long Cypher Restenosis Rate % 5 SES (n=11) BMS (n=79) P<.1 P<.1 P=.2 P= In-segment Proximal edge In-stent Distal edge
33 Long Cypher Pattern of 3 Restenotic Cases % SES (n=3) 54.8 BMS (n=42) LAD 23 x 18, Focal, distal instent 54% LCX 28 x 23, Focal, distal instent 56% RCA, 33 x 23, Focal, overlapping area 82% Focal Diffuse Proliferative Total
34 Why not stent-overlap? Multiple Stent vs. Single Stent
35 Impact of Stent Overlapping SIRIUS : Sirolimus Eluting Stent Late loss (mm) In-stent In-segment Restenosis (%) In-stent In-segment Sirolimus (n=176) Control (n=168) P value <.1 <.1 <.1 <.1 TCT, Oct 22
36 Restenosis in > 1 Stent in stented segment TAXUS II : Paclitaxel Eluting Stent % P = Combined control (n=19). Combined TAXUS (n=14) Grube E, ACC, 23
37 Impact of Multiple Stents 6 5 Restenosis (analysis segment) TAXUS IV Control (n=267) TAXUS (n=291) 46.2 Restenosis P<.1 P= N=253 N=276 N=13 Single stent Multiple stents N=15
38 % 6 Restenosis Rate According to Multiple Stenting Long Cypher SES BMS P< Multiple stent 39.7 P<.1 Single stent N
39 Restenosis Rate According to % 5 4 Stent Overlap Long Cypher SES (n=56) BMS (n=2) P< Overlap site P< Non-overlap site
40 Area Change of Overlap Site Long Cypher mm Post-intervention Follow-Up P< Total 29 available lesions P<.1 P<.1 EEM P+M Lumen
41 Stent-overlap did not show any difference mm Area changes at 6 months F/U P=.68 Long Cypher Worst site in non-overlap Worst site in overlap P=.689 P= EEM P+M Lumen
42 Shift of an Idea for Long Lesion with DES the longer, the better Full lesion coverage Acceptance of stent-overlap
43 In Subgroups Does it applied to all patients and lesion subsets?
44 Long Cypher Restenosis Rate in DM % 6 SES (n=3) BMS (n=31) P< P<.1 P=.238 P= In-segment Proximal edge In-stent Distal edge
45 Long Cypher Restenosis Rate in LAD % 4 SES (n=73) BMS (n=39) P<.1 P= P<.1 P= In-segment Proximal edge In-stent Distal edge
46 Restenosis Rate in Long Cypher Acute Coronary Syndrome % SES (n=55) BMS (n=45) P<.1 P<.1 P=.88 P= In-segment Proximal edge In-stent Distal edge
47 Restenosis Rate in Long Cypher Small Vessel (<3.mm) % SES (n=76) BMS (n=5) P< P=.9 1 P< P=.1 In-segment Proximal edge In-stent Distal edge 14
48 Restenosis Rate According to Reference Diameter Long Cypher % 6 SES BMS P< P<.1 < > P=.544 N
49 Angiographic Restenosis SES BMS P-value Overall Male Female Diabetes No Diabetes LAD Non-LAD Small Vessel (<2.75) Large Vessel ACS Non ACS Overlap No Overlap < < < < < < < < < <.1 Hazards Ratio 95% CI Sirolimus better
DES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationPCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationFFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
More informationEffect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationPercutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
More informationIn-Stent Restenosis. Can we kill it?
In-Stent Restenosis Can we kill it? However, In-stent Restenosis is the most serious problem (2-25%) More than 15, lesions will need treatment because of in-stent restenosis. Varying Prevalence Rates of
More informationJournal of the American College of Cardiology Vol. 46, No. 5, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 46, No. 5, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.06.009
More informationSide Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
More informationBasics of Angiographic Interpretation Analysis of Angiography
Basics of Angiographic Interpretation Analysis of Angiography Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Seoul, Korea What made us nervous Supervisors Stent Contrast
More informationFFR and IVUS Guided DES Implantation in Long Diffuse Lesions
FFR and IVUS Guided DES Implantation in Long Diffuse Lesions Can We Reach Optimal DES Expansion With Conventional Stent Delivery System in Long Diffuse Lesion? Seung-Jea Tahk, MD., PhD. Ajou University
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationEBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb
EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb A. Medina Servicio de Cardiología Hospital Universitario de Gran Canaria Dr. Negrín Islas Canarias (Spain) Provisional
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationFinal Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
More informationIntegrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
More informationWhy I try to avoid side branch dilatation
Why I try to avoid side branch dilatation Hyeon-Cheol Gwon Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Why I don t kiss? I kiss! I prefer to discuss SB ballooning rather
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More informationPCI for Bifurcation Coronary Lesion
PCI for Bifurcation Coronary Lesion Bifurcation Lesions PCI is Challenging Higher acute complication Lower success rates Higher restenosis & TLR Restenosis Rate 21 ~ 57% TLR 8 ~ 43% Event Free Survival
More informationDeclaration of conflict of interest. Nothing to disclose
Declaration of conflict of interest Nothing to disclose Hong-Seok Lim, Seung-Jea Tahk, Hyoung-Mo Yang, Jin-Woo Kim, Kyoung- Woo Seo, Byoung-Joo Choi, So-Yeon Choi, Myeong-Ho Yoon, Gyo-Seung Hwang, Joon-Han
More informationProtection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationIVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
More informationWhy Polymer Coated Paclitaxel Stents
Why Polymer Coated Paclitaxel Stents Insight from Clinical Trials Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, University of Ulsan, Seoul, Korea Why Paclitaxel? Stable
More informationManagement of Non-protected Left-Main Bifurcation without Drug Eluting Stent. Masahiko Ochiai MD, FACC, FESC, FSCAI
Management of Non-protected Left-Main Bifurcation without Drug Eluting Stent Masahiko Ochiai MD, FACC, FESC, FSCAI Division of Cardiology and Cardiovascular Surgery Showa University Northern Yokohama Hospital
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationUpgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
More informationBetween Coronary Angiography and Fractional Flow Reserve
Visual-Functional Mismatch Between Coronary Angiography and Fractional Flow Reserve Seung-Jung Park, MD., PhD. University of Ulsan, College of Medicine Asan Medical Center, Seoul, Korea Visual - Functional
More informationIVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.
Left Main and Bifurcation Summit IVUS-Guided d Provisional i Stenting: ti Plaque or Carina Shift Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan College of Medicine Asan Medical Center,
More informationLeft Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More informationInsight from the CACTUS trial Coronary Bifurcation Application of the Crush
EBC - Prague 26-28 september 2008 Insight from the CACTUS trial The role of final kissing balloon inflation F. Airoldi,, A. Colombo San Raffaele Scientific Institute EMO Centro Cuore,, Columbus Hospital
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationCulprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome
Culprit Lesion Remodeling and Long-term (> 5years) Prognosis in Patients with Acute Coronary Syndrome Hiroyuki Okura*, MD; Nobuya Matsushita**,MD Kenji Shimeno**, MD; Hiroyuki Yamaghishi**, MD Iku Toda**,
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationLate Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance
Late Loss Is The Single Best Parameter For Estimating Stent-Based Restenosis Resistance Richard Kuntz Brigham and Women s s Hospital Harvard Medical School Late Loss and DES Brief history of Late Loss
More informationClinical Considerations for CTO
38 RCTs Clinical Considerations for CTO 18,000 pts Revascularization Whom to treat, Who derives benefit and What can we achieve? David E. Kandzari, MD FACC, FSCAI Director, Interventional Cardiology Research
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationIVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation
IVUS Assessment of the Mechanism of In-stent Restenosis? Gary S. Mintz, MD Cardiovascular Research Foundation SURE Trial: Restenosis in non-stented lesions Average of the two image slices with the smallest
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationA Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI
HORIZONS-AMI: A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Gregg W. Stone
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationLeft Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationThe MAIN-COMPARE Registry
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationA Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
More informationCoronary Artery Stenosis. Insight from MAIN-COMPARE Study
PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice
More information6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France
6 th European Bifurcation Club 22-23 October 2010 - BUDAPEST Kissing in simple strategy? Why and how I kiss Y. Louvard, ICPS, Massy France A long experience of kissing 1996 Patients 79 Final Kissing balloon
More informationStrategies for PCI of SVG
Strategies for PCI of SVG Ron Waksman, MD, FACC Augusto Pichard, MD, FACC Washington Hospital Center, Washington DC OPTIONS FOR IMPROVED OUTCOMES IN SVG PCI Direct Stenting Thrombus Management Embolic
More informationSo-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of Medicine, Korea
So-Yeon Choi, MD., PhD. Department of Cardiology Ajou University School of Medicine, Korea Anatomical vs Functional Significance? Coronary Angiogram Treadmill Test Tc-99m-MIBI SPECT MDCT Coronary Angiogram
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationDebate Should we use FFR? I will say NO.
Debate Should we use FFR? I will say NO. Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol Gwon Research fund from Abbott Korea
More informationPlaque Shift vs. Carina Shift Prevalence and Implication
TCTAP 2013 Fellowship Course Left Main and Bifurcation PCI: Bifurcation PCI Plaque Shift vs. Carina Shift Prevalence and Implication Soo-Jin Kang, MD., PhD. Department of Cardiology, University of Ulsan
More informationPrognostic Value of Gated Myocardial Perfusion SPECT
Current Use of IVUS & FFR George D. Dangas, MD, PhD, FACC, FSCAI Professor of Medicine Mount Sinai School of Medicine Prognostic Value of Gated Myocardial Perfusion SPECT 0.6% / year, Cardiac Death and
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationSunao Nakamura M.D,Ph.D.
Drug Eluting Stent Implantation For Unprotected Left ain Coronary Arteries New Tokyo Circulation Research Group New Tokyo Hospital Sunao Nakamura.D,Ph.D. Drug-Eluting Stent for Left ain Coronary Artery
More informationIntegrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes. Gary S. Mintz, MD Cardiovascular Research Foundation
Integrating IVUS, FFR, and Noninvasive Imaging to Optimize Outcomes Gary S. Mintz, MD Cardiovascular Research Foundation COURAGE Nuclear Substudy (n=314) Death/MI according the residual ischemia (SPECT)
More informationPeriprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion
Periprocedural Myocardial Infarction and Clinical Outcome In Bifurcation Lesion Hyeon-Cheol Gwon Cardiac and Vascular Center Samsung Medical Center Sungkyunkwan University School of Medicine Dr. Hyeon-Cheol
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationSirolimus-Eluting Stents for Treatment of In-Stent Restenosis
Clinical Investigation Alfonso Medina, MD José Suárez de Lezo, MD Manuel Pan, MD Antonio Delgado, MD José Segura, MD Djordje Pavlovic, MD Francisco Melián, MD Miguel Romero, MD Federico Segura, MD Enrique
More informationINDEX 1 INTRODUCTION DEVICE DESCRIPTION CLINICAL PROGRAM FIRST-IN-MAN CLINICAL INVESTIGATION OF THE AMAZONIA SIR STENT...
May 2017 INDEX 1 INTRODUCTION... 2 2 DEVICE DESCRIPTION... 3 ANTI-PROLIFERATIVE DRUG - SIROLIMUS... 3 BIODEGRADABLE POLYMERS... 3 SIROLIMUS CONTROLLED ELUTION... 4 STENT PLATFORM... 4 3 CLINICAL PROGRAM...
More informationUnprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationDESolve NX Trial Clinical and Imaging Results
DESolve NX Trial Clinical and Imaging Results Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese, Sao Paulo, Brazil On behalf of the DESolve Nx Trial Investigators Please refer to the TCT2014 App or
More informationCount Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationKey Words Angioplasty Coronary artery disease Revascularization Stent drug eluting stent
J Cardiol 26 Dec; 48 6 : 325 331 3 mm : Initial and Mid-Term Effects of 3 mm Long Sirolimus-Eluting Stents in Patients With Diffuse Long Coronary Lesions: Comparison With Bare Metal Stents Abstract Yosuke
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationStent Fracture and Longitudinal Compression on CT Angiography between the
2014 ASCI Stent Fracture and Longitudinal Compression on CT Angiography between the First- and New-Generation Drug-Eluting Stent Mi Sun Chung, Dong Hyun Yang,Young-Hak Kim, Jae-Hyung Roh, Joon-Won Kang,
More informationTrial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)
Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of
More informationThe SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
More informationRevascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
More informationRESTENOSIS Facing up to the problem
RESTENOSIS Facing up to the problem Petr Kala University Hospital Brno Czech Republic ESC 2011, Paris Disclosure Scientific Advisory Boards or Education presentations fee Abbott, Boston Scientific, Cordis
More informationInspiron Stent. Clinical Research Program. Pedro A. Lemos MD PhD. Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil
Stent Clinical Research Program Pedro A. Lemos MD PhD Heart Institute InCor University of Sao Paulo Medical School Sao Paulo Brazil All faculty disclosures are available on the CRF Events App and online
More informationThe Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results
The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results Dr. VIVEK GUPTA MD, DM, FICC, FIC France Senior Interventional Cardiologist Indraprastha Apollo
More informationUpdate from the Tryton IDE study
Update from the Tryton IDE study Maciej Lesiak EBC 2015 - Athens The Tryton Bifurcation Trial: A randomized comparison of a provisional one-stent vs. a dedicated two-stent strategy for true bifurcation
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationBifurcation Stenting: IVUS and OCT Information
Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon Proximal stent deformation induced by
More informationStents selection and optimal implantation: sizes, design, deployment Abbott Vascular. All rights reserved.
Stents selection and optimal implantation: sizes, design, deployment Stent classification: Mechanism of expansion - Self-expanding - Balloon expandable Design - Mesh structure - Coil - Slotted tube - Ring
More informationSirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations
Journal of the American College of Cardiology Vol. 55, No. 16, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.02.008
More information